Obese patients have increased cardiovascular risk and target organ damage (TOD) as compared to people with normal weight. Weight loss reduces cardiovascular risk and TOD. These changes have been associated mainly to changes in inflammatory and pro-atherogenic markers. Office peripheral blood pressure (BP) appears to decrease after bariatric surgery, but information on changes in 24h-ambulatory-BP-monitoring (24h-ABPM) and central-BP(cBP), or about the possible role of renin-angiotensin-aldosterone (RAAS), serotonin(STS) and endocannabinoid(ECS) systems is scarce. Our hypothesis is that the hemodynamic changes mediated by alterations in the RAAS, STS and ECS after weight loss are also responsible for the reduction of TOD.
Study Type
OBSERVATIONAL
Enrollment
50
Hospital del Mar_Nefrology
Barcelona, Spain
Mean changes 24h-aortic systolic-blood pressure (SBP) measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean changes in aortic- 24h, daytime and nighttime blood pressure estimates others than 24h systolic blood pressure measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean changes in peripheral- 24h, daytime and nighttime blood pressure estimates measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in office blood pressure estimates measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in arterial stiffness parameters (I)
pulse wave velocity measured in m/s
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in arterial stiffness parameters (II)
augmentation index measured in %
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Left ventricular mass index
Left ventricular mass index measured in g/m2
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Left atrium diameter
Left atrium diameter measured in mm
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Ejection fraction
Ejection fraction measured in %,
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in left ventricular remodeling index
left ventricular remodeling index, do not have units
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in carotid intima-media thickness measured in mm
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in biochemical parameters measured in mg/dl or mmol/L
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the components of the renin-angiotensin system
renin-angiotensin system: plasma renin activity: ng/mL/h, plasma aldosterone: pg/ml, angiotensinogen: mng/100ml, angiotensin 1-7: pg/ml, ACE: UI/l, ACE-2: UI/I
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the serotonergic system components
serotonergic system: 5-HIAA:ng/ml, 5-HT:ng/mL
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the components of the endocannabinoid system
endocannabinoid system: Anandamide: nmol/mL, 2-arachidonoylglycerol: mg/ml
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in pro-atherosclerotic markers
pro-atherosclerotic markers: omentine-1: ng/ml, chemerine: ng/ml, leptin: ng/ml, adiponectine: mcg/ml
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.